[go: up one dir, main page]

ATE466931T1 - Verbesserte adenovirusvektoren - Google Patents

Verbesserte adenovirusvektoren

Info

Publication number
ATE466931T1
ATE466931T1 AT97946337T AT97946337T ATE466931T1 AT E466931 T1 ATE466931 T1 AT E466931T1 AT 97946337 T AT97946337 T AT 97946337T AT 97946337 T AT97946337 T AT 97946337T AT E466931 T1 ATE466931 T1 AT E466931T1
Authority
AT
Austria
Prior art keywords
vectors
deleted
adenoviral
improved
gutted
Prior art date
Application number
AT97946337T
Other languages
English (en)
Inventor
Jeffrey Chamberlain
Andrea Amalfitano
Michael Hauser
Rajendra Kumar-Singh
Dennis Hartigan-O'connor
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE466931T1 publication Critical patent/ATE466931T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97946337T 1996-10-23 1997-10-23 Verbesserte adenovirusvektoren ATE466931T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/735,609 US5994132A (en) 1996-10-23 1996-10-23 Adenovirus vectors
PCT/US1997/019541 WO1998017783A1 (en) 1996-10-23 1997-10-23 Improved adenovirus vectors

Publications (1)

Publication Number Publication Date
ATE466931T1 true ATE466931T1 (de) 2010-05-15

Family

ID=24956492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946337T ATE466931T1 (de) 1996-10-23 1997-10-23 Verbesserte adenovirusvektoren

Country Status (6)

Country Link
US (5) US5994132A (de)
EP (1) EP0935648B1 (de)
AT (1) ATE466931T1 (de)
AU (1) AU5152998A (de)
DE (1) DE69739870D1 (de)
WO (1) WO1998017783A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US20060110798A1 (en) * 1995-06-07 2006-05-25 Graham Frank L Cells expressing recombinase useful for adenovirus vector production and control of gene expression
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6328958B1 (en) 1998-08-28 2001-12-11 Duke University Deleted adenovirus vectors and methods of making and administering the same
CA2359795A1 (en) * 1999-01-14 2000-07-20 Novartis Ag Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
JP2000279178A (ja) * 1999-02-24 2000-10-10 Japan Found Cancer Res ウイルスベクター
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2382185A1 (en) * 1999-06-11 2000-12-21 Human Genome Sciences, Inc. 48 human secreted proteins
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
AU1453501A (en) * 1999-11-10 2001-06-06 Genzyme Corporation Ptp/dna polymerase cell line as packaging cell line for minimal adenoviral vectors
AU1817401A (en) * 1999-12-14 2001-06-25 Genovo, Incorporated Methods and compositions for the manufacture of replication incompetent adenovirus
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
US6562955B2 (en) * 2000-03-17 2003-05-13 Tosoh Corporation Oligonucleotides for detection of Vibrio parahaemolyticus and detection method for Vibrio parahaemolyticus using the same oligonucleotides
CN100422320C (zh) * 2000-04-28 2008-10-01 肖啸 编码抗肌萎缩蛋白小基因的dna序列及其使用方法
AU2001258102B2 (en) 2000-05-10 2007-03-01 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
DE60140052D1 (de) * 2000-05-31 2009-11-12 Human Gene Therapy Res Inst Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
WO2002006495A2 (en) * 2000-07-14 2002-01-24 The Regents Of The University Of Michigan Mutant muscle-specific enhancers
EP1365794A2 (de) * 2000-07-21 2003-12-03 Lue, Tom Vorbeugung und behandlung von störungen der sexuellen erregbarkeit
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2002027007A2 (en) 2000-09-25 2002-04-04 Regents Of The University Of Michigan Production of viral vectors
GB2368064B (en) * 2000-09-30 2002-11-13 Imp Cancer Res Tech DNA Element and Associated Protein
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
EP1373858A1 (de) 2001-03-07 2004-01-02 THE TEXAS A&M UNIVERSITY SYSTEM Dichtegradientenlösungen von metallionen-chelatkomplexen
DE60232785D1 (de) 2001-03-14 2009-08-13 Myriad Genetics Inc Tsg101-gag-wechselwirkung und ihre verwendung
US6943012B2 (en) 2001-03-26 2005-09-13 The Board Of Trustees Of The Leland Stanford Junor University Helper dependent adenoviral vector system and methods for using the same
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
US7449562B2 (en) * 2001-06-29 2008-11-11 Novartis Ag PERV screening method and use thereof
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
WO2003010306A1 (en) * 2001-07-23 2003-02-06 Onyx Pharmaceuticals, Inc. Viral mutants that selectively replicate in targeted human cancer cells
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
DE10150984A1 (de) * 2001-10-16 2003-04-17 Holm Per Sonne Verwendung des adenoviralen E2-late-Promotors
WO2003033723A2 (en) * 2001-10-18 2003-04-24 Aventis Pharmaceuticals Inc. Vectors for expressing multiple transgenes
EP1308517A1 (de) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vektoren für die Expression von mehrere Transgenen
US20030165954A1 (en) 2002-01-09 2003-09-04 Third Wave Technologies, Inc. Cancer profiles
ATE517122T1 (de) 2002-04-09 2011-08-15 Sanofi Pasteur Ltd Modifizierte cea-nukleinsäure und entsprechende expressionsvektoren
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
US20060099178A1 (en) 2002-05-27 2006-05-11 Holm Per S Novel use of adenoviruses and nucleic acids coding therefor
AU2003298768A1 (en) * 2002-12-02 2004-06-23 Biovec Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US7803365B2 (en) * 2002-12-02 2010-09-28 Biovec, Llc Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20050106124A1 (en) * 2003-02-25 2005-05-19 Sehgal Lakshman R. Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
EP1639090A4 (de) * 2003-06-09 2008-04-16 Univ Michigan Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
EP1944318B1 (de) 2003-07-21 2011-03-02 Transgene S.A. Multifunktionelle Cytokine
EP1670926B1 (de) * 2003-10-08 2011-04-20 Sanofi Pasteur Limited Modifizierter cea/b7-vektor
CA2546178A1 (en) 2003-11-14 2005-06-09 Per Sonne Holm New use of adenovirus and nucleic acids coding therefor
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005115477A2 (en) * 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
WO2005117990A2 (en) * 2004-04-20 2005-12-15 Duke University Compositions and methods for treatment of vascular grafts
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
WO2006042017A2 (en) 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
US20070298458A1 (en) * 2004-11-18 2007-12-27 National University Of Corporation Hiroshima University Method And Kit For Expressing Protein Under Regulation Of The Expression From Repeated Sequence Formed By Gene Amplification, And Transformant
WO2007046826A2 (en) * 2004-12-01 2007-04-26 The Regents Of The University Of Michigan Compositions and methods for regulating cardiac performance
US8999944B2 (en) 2005-01-20 2015-04-07 University Of Rochester Thioredoxin interacting protein (TXNIP) as regulator of vascular function
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2814598A1 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2007047907A2 (en) * 2005-10-14 2007-04-26 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
ES2641087T3 (es) 2005-10-31 2017-11-07 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y el tratamiento del cáncer
AU2006308847C1 (en) * 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2377953A1 (de) 2006-06-23 2011-10-19 Myriad Genetics, Inc. Varianten des DPYD-Gens und ihre Verwendung
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
WO2008010991A2 (en) 2006-07-17 2008-01-24 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
WO2008030605A2 (en) * 2006-09-08 2008-03-13 The Regents Of The University Of Michigan Herv group ii viruses in lymphoma and cancer
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
US8148147B2 (en) * 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
JP5529732B2 (ja) 2007-07-06 2014-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
EP2179292B1 (de) 2007-08-16 2012-11-28 The Regents of the University of Michigan Metabolomische profilierung von prostatakrebs
JP2010540681A (ja) * 2007-10-08 2010-12-24 クインテッセンス バイオサイエンシズ，インコーポレーテッド リボヌクレアーゼに基づく治療のための組成物及び方法
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
US8193151B2 (en) * 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
CN105079805A (zh) 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
WO2010081001A2 (en) 2009-01-09 2010-07-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
CA3120504A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
EP2548025A4 (de) 2010-03-17 2013-09-25 Univ Michigan Verwendung von phagenepitopen zur profilierung einer immunreaktion
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2012092341A1 (en) 2010-12-28 2012-07-05 University Of Rochester Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
US20140155469A1 (en) 2011-04-19 2014-06-05 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors and viruses
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
PL2729173T3 (pl) 2011-07-06 2017-06-30 Sykehuset Sorlandet Hf Terapia nacelowana na egfr
EP2753346B1 (de) 2011-09-07 2020-04-22 Mount Sinai School Of Medicine Ceramidase und zelldifferenzierung
MX354516B (es) 2011-10-27 2018-03-08 Wellstat Ophthalmics Corp Vectores que codifican el factor de viabilidad de conos derivado de bastones.
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2908853B1 (de) 2012-10-21 2018-12-05 University Of Rochester Thy1 (cd90) als therapie zur steuerung von fettgewebeakkumulation
JP6430949B2 (ja) 2012-10-23 2018-11-28 エモリー ユニバーシティ Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
US20150320861A1 (en) 2012-12-21 2015-11-12 Sykehuset Sørlandet Hf Egfr targeted therapy of neurological disorders and pain
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
EP2992112B1 (de) 2013-04-22 2020-06-03 Icahn School of Medicine at Mount Sinai Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
EP3062884B1 (de) 2013-10-29 2020-12-02 President and Fellows of Harvard College Zusammensetzungen zur verwendung in der behandlung von retinitis pigmentosa
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
AU2016205215B2 (en) 2015-01-09 2021-03-11 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
EP3371211B1 (de) 2015-11-04 2025-01-01 Icahn School of Medicine at Mount Sinai Rho-assoziierte proteinkinasehemmer zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
US10669320B2 (en) 2015-11-18 2020-06-02 The Regents Of The University Of Michigan Mps1 and KNL1 phosphorylation system
EP3411474A4 (de) * 2016-02-05 2019-09-11 Nant Holdings IP LLC Zusammensetzungen und verfahren zur expression von rekombinantem cxadr
EP3448881B1 (de) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Behandlung von hippo-pfad-mutanten tumoren und verfahren zur identifizierung von probanden als kandidaten für die behandlung
MX2018014602A (es) 2016-05-27 2019-06-10 Etubics Corp Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
US11241436B2 (en) 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
WO2019103967A1 (en) 2017-11-22 2019-05-31 The Regents Of The University Of Michigan Compositions and methods for treating cancer
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
CN111836639A (zh) 2018-01-26 2020-10-27 河谷细胞有限公司 用于联合癌症疫苗和免疫辅助疗法的组合物和方法
US20220184232A1 (en) * 2019-03-25 2022-06-16 The Regents Of The University Of California Methods of treating tnni3-mediated cardiomyopathy
JP7457733B2 (ja) * 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
EP3990000A1 (de) 2019-06-28 2022-05-04 Nantcell, Inc. Pharmazeutische zusammensetzungen zur verbesserung der phagozytose ohne entzündung
KR102371663B1 (ko) * 2020-01-21 2022-03-04 코오롱생명과학 주식회사 아데노바이러스 벡터
WO2021183717A1 (en) 2020-03-11 2021-09-16 Nantcell, Inc. Proteinaceous therapeutics
JP2023520610A (ja) * 2020-03-28 2023-05-17 グレフェックス， インコーポレイテッド 真核細胞におけるｄｎａ断片の維持、手法、および使用
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine
WO2022035863A1 (en) 2020-08-11 2022-02-17 Musculoskeletal Transplant Foundation Method for treating cardiac conditions with placenta-derived compositions
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
US20240327492A1 (en) 2021-07-29 2024-10-03 Nantcell, Inc. Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer
EP4335870A1 (de) 2022-09-06 2024-03-13 NantCell, Inc. Peptidtherapeutika gegen das sars-cov-2-spike-protein
US20240342313A1 (en) 2023-03-30 2024-10-17 Pharma Cinq, Llc Vector encoding rod-derived cone viability factor and human igk signal sequence

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0787200B1 (de) * 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
DE69628744D1 (de) 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helfervirus system
WO1997032481A1 (en) * 1996-03-07 1997-09-12 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy

Also Published As

Publication number Publication date
US6083750A (en) 2000-07-04
US5994132A (en) 1999-11-30
EP0935648A4 (de) 2004-11-17
WO1998017783A1 (en) 1998-04-30
US6451596B1 (en) 2002-09-17
EP0935648B1 (de) 2010-05-05
EP0935648A1 (de) 1999-08-18
US6063622A (en) 2000-05-16
US6057158A (en) 2000-05-02
DE69739870D1 (de) 2010-06-17
AU5152998A (en) 1998-05-15

Similar Documents

Publication Publication Date Title
ATE466931T1 (de) Verbesserte adenovirusvektoren
ES2151310T3 (es) Nuevas lineas celulares de complementacion para vectores adenovirales defectivos.
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
Parks et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal
ATE256196T1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
CA2391591A1 (en) Permanent amniocyte cell line, the production thereof and its use for producing gene transfer vectors
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
WO2000012740A3 (en) Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
MX9702553A (es) Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.
WO1998027204A3 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
AU2812484A (en) Dna vectors and there use in recombinant dna technology
CA2104396A1 (en) Viral particles having altered host range
JP2003514526A5 (de)
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
ATE403736T1 (de) Onkolytische adenovirale vektoren
AUPN477695A0 (en) Gene therapy
AU5551996A (en) An adenovirus helper-virus system
SG91252A1 (en) Herpesvirus saimiri as viral vector
AU5318496A (en) Adenovirus vectors for gene therapy
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
Kaplan et al. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes
SE8604636L (sv) Sett att uttrycka gener med hjelp av bacillus brevis
WO2000022136A3 (en) Recombinant e1a deleted adenoviral vectors
WO2000029573A3 (en) Adenoviral vectors
Orum et al. Sequence and proposed secondary structure of the Tetrahymena thermophila U3-snRNA

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties